

Received Date: September 13, 2024 **Accepted Date:** October 11, 2024 **Published Date:** November 11, 2024

Available Online at <https://www.ijsrisjournal.com/index.php/ojsfiles/article/view/199>

<https://doi.org/10.5281/zenodo.14082271>

Post-Traumatic Stress Disorder: A Review of Current Causes and Treatment

Amal tawfiq al arooj¹, Laila Nasser Al-Hassan², Salma nassir alquraish³, Eman Jaber Alsaeed⁴, Fatimah Abdulelah Alsulis⁵, Adraa ibrahim alshoreet¹, Haidar mahdi albeladi¹, Bdoor ahmed salbookh¹, Wadeah ismail albasha⁶, Hadeer Habib Alshwaikhat⁴, Mona salman alrwaimi⁷, Khadijah Hussain Alhijji⁴, Entidhar AbdAlrouf Bu keder⁴, Zainab Ahmed Al-Hassan⁸

1. King Fahad al Hofuf hospital (Al Jaber kidney center) , Saudi Arabia.
2. Al-Ahsa Health Cluster - Immunization Department at Al-Thulaiithiya Health Center, Saudi Arabia.
3. Abdulaziz bin Sulaiman Al-Afaliq Center for Early Detection of Tumors, Saudi Arabia.
4. Prince Saud bin Jalawi Hospital, Saudi Arabia.
5. Maternity and children Hospital in DAMMAM, Saudi Arabia.
6. Fouda Health Center, Saudi Arabia.
7. Maternity and Children's Hospital in Al-Ahsa, Saudi Arabia.
8. Maternity And Children Hospital, Saudi Arabia.

ABSTRACT

Post-Traumatic Stress Disorder (PTSD) is a severe and often chronic mental health condition that arises following exposure to traumatic events. It affects millions worldwide, leading to significant emotional, physical, and social impairments. This review provides an overview of current understanding regarding the causes of PTSD, including risk factors, biological mechanisms, and psychological influences, as well as the treatments available, focusing on both established and emerging therapeutic approaches.

Keywords: Post-Traumatic Stress Disorder, psychotherapy, medication.

1. Introduction

Posttraumatic stress disorder (PTSD) is an anxiety problem that may develop in some people after exposure to extremely traumatic events, such as combat, crime, an accident, or a natural disaster(1). In any given year, 7.7 million Americans over the age of 18 are diagnosed with PTSD, (2)a debilitating disorder that is often comorbid with other diseases(3). Individuals with PTSD suffer substantial social and interpersonal problems, as well as impaired quality of life stemming from the long-term presence of the intrusive, avoidant and hyperaroused symptoms that characterize the disease. Concomitantly, PTSD patients show characteristics of higher sympathetic and lower parasympathetic activity at basal levels compared to healthy individuals(4)as measured by low heart rate variability (HRV)(5). Although conventional pharmacologic and psychotherapeutic interventions have shown some proven efficacy in the treatment of PTSD(6), residual symptoms and therapeutic efficacy remain problematic. Recently, a variety of integrative mind-body intervention modalities have emerged that are increasingly employed in the treatment of PTSD.

PTSD develops in some individuals who have experienced or witnessed traumatic events, such as natural disasters, combat, assault, or severe accidents. Symptoms include intrusive thoughts, flashbacks, avoidance, heightened arousal, and negative changes in cognition and mood. While not everyone exposed to trauma develops PTSD, certain factors increase susceptibility. Additionally, numerous treatment options exist, with advances continuing to improve outcomes for those affected.

2. Causes of PTSD

PTSD is a multifactorial condition influenced by genetic, biological, psychological, and social factors.

2.1 Genetic and Biological Factors

Genetics contribute to PTSD susceptibility, with studies suggesting heritability rates of about 30-40%(7). Certain genes related to serotonin and dopamine regulation, such as the serotonin transporter gene (5-HTTLPR), have been linked to increased PTSD risk.

On a biological level, PTSD is associated with changes in the brain's stress-response system. The hypothalamic-pituitary-adrenal (HPA) axis, which regulates stress hormones like cortisol, may be dysregulated in PTSD patients, leading to exaggerated or prolonged stress responses (8). Neuroimaging studies have also shown structural and functional abnormalities in brain areas involved in fear and memory, including the amygdala, hippocampus, and prefrontal cortex (9).

2.2 Psychological and Social Factors

Psychological factors, such as previous exposure to trauma, lack of social support, and certain personality traits (e.g., high levels of neuroticism), can increase PTSD risk. Childhood adversity, especially early abuse or neglect, has been shown to have a lasting impact on vulnerability to PTSD later in life. Social factors, including low socioeconomic status and limited access to mental health resources, further contribute to the development and severity of PTSD.

2.3 Cognitive and Behavioral Models

Cognitive models of PTSD emphasize the role of maladaptive beliefs about oneself, others, and the world, which can reinforce symptoms and hinder recovery. For instance, trauma survivors with heightened self-blame or fear of future harm may be more prone to developing PTSD(10). Behavioral models suggest that avoidance behaviors, a common response in PTSD, can prevent trauma processing, reinforcing the cycle of symptoms (11).

3. Treatment Options for PTSD

A range of evidence-based treatments are available for PTSD, including psychotherapies, medications, and alternative therapies.

3.1 Psychotherapy

Psychotherapy is considered the first-line treatment for PTSD and includes several well-supported approaches.

- **Cognitive Behavioral Therapy (CBT):** CBT, particularly trauma-focused CBT, has been extensively validated for PTSD treatment. Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE) are two forms of trauma-focused CBT shown to reduce PTSD symptoms by helping individuals confront and re-evaluate traumatic memories and beliefs (11).
- **Eye Movement Desensitization and Reprocessing (EMDR):** EMDR combines exposure therapy with guided eye movements, which may help process and integrate traumatic memories. Studies show EMDR can be as effective as CBT for some PTSD patients(12).
- **Narrative Exposure Therapy (NET):** NET is often used for individuals who have experienced multiple traumas, such as refugees or survivors of prolonged abuse. It involves creating a detailed narrative of the person's life and traumatic events to help them process trauma in a structured way

3.2 Pharmacotherapy

While psychotherapy is the preferred approach for PTSD, medications can help alleviate specific symptoms, particularly for those unable or unwilling to engage in therapy.

- **Selective Serotonin Reuptake Inhibitors (SSRIs):** SSRIs, such as sertraline and paroxetine, are commonly prescribed for PTSD due to their effectiveness in managing anxiety, depression, and intrusive symptoms (13). These are often the first-line medications recommended for PTSD.
- **Prazosin:** Prazosin, an alpha-1 adrenergic receptor antagonist, has shown effectiveness in reducing nightmares and sleep disturbances associated with PTSD, although recent studies have provided mixed results regarding its overall efficacy (14)
- **Other Medications:** Other medications, such as serotonin-norepinephrine reuptake inhibitors (SNRIs) and antipsychotics, are sometimes used, particularly for patients with treatment-resistant PTSD. However, they are generally considered second-line options due to limited evidence of effectiveness and potential side effects(15)

3.3 Emerging and Alternative Treatments

Research into alternative and emerging treatments for PTSD is ongoing, with some promising approaches showing potential in clinical trials.

- **Ketamine:** Ketamine, an NMDA receptor antagonist, has been studied for its rapid antidepressant effects, and recent studies indicate it may help alleviate PTSD symptoms in some patients, though more research is needed (16).
- **MDMA-Assisted Therapy:** MDMA, commonly known as ecstasy, is being investigated for use in PTSD treatment in conjunction with psychotherapy. Clinical trials have shown that MDMA-assisted therapy can lead to significant improvements in PTSD symptoms, and it has received breakthrough therapy designation by the U.S. FDA (17).
- **Mindfulness and Yoga:** Mindfulness-based practices, including mindfulness meditation and yoga, have gained attention as complementary therapies for PTSD. These approaches help individuals focus on the present moment, potentially reducing hyperarousal and improving emotional regulation (18).
- **Virtual Reality Exposure Therapy (VRET):** VRET involves using virtual reality technology to simulate traumatic events in a controlled setting, allowing patients to confront their trauma safely. It has shown promise in military veterans and other groups with combat-related PTSD(19)

4. Conclusion

PTSD remains a complex and challenging disorder, with various genetic, biological, and psychosocial factors influencing its development. Current treatment options, primarily involving psychotherapy and medication, have demonstrated effectiveness, but they are not universally effective for all individuals. Emerging treatments, including MDMA-assisted therapy, ketamine, and mindfulness-based practices, offer hope for those who do not respond to traditional approaches.

Further research is essential to understand the mechanisms underlying PTSD and develop more personalized treatments. Meanwhile, increasing awareness and accessibility to effective interventions can help reduce the burden of PTSD on individuals and society.

References

1. GUZE SB. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). American Journal of Psychiatry. 1995;152(8).
2. Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in U.S. adolescents: Results from the national comorbidity survey replication-adolescent supplement (NCS-A). *J Am Acad Child Adolesc Psychiatry*. 2010 Oct;49(10):980–9.
3. Libby DJ, Pilver CE, Desai R. Complementary and alternative medicine use among individuals with posttraumatic stress disorder. *Psychol Trauma*. 2013;5(3).
4. Blechert J, Michael T, Grossman P, Lajtman M, Wilhelm FH. Autonomic and respiratory characteristics of posttraumatic stress disorder and panic disorder. In: *Psychosomatic Medicine*. 2007.
5. Streeter CC, Gerbarg PL, Saper RB, Ciraulo DA, Brown RP. Effects of yoga on the autonomic nervous system, gamma-aminobutyric-acid, and allostasis in epilepsy, depression, and post-traumatic stress disorder. *Med Hypotheses*. 2012;78(5).
6. Cukor J, Spitalnick J, Difede JA, Rizzo A, Rothbaum BO. Emerging treatments for PTSD. Vol. 29, *Clinical Psychology Review*. 2009.
7. Radhakrishnan K, Aslan M, Harrington KM, Pietrzak RH, Huang G, Muralidhar S, et al. Genomics of posttraumatic stress disorder in veterans: Methods and rationale for Veterans Affairs Cooperative Study #575B. *Int J Methods Psychiatr Res*. 2019;28(1).
8. Rase-Abdullahi P, Meamar M, Vafaei AA, Alizadeh M, Dadkhah M, Shafia S, et al. Hypothalamus and Post-Traumatic Stress Disorder: A Review. Vol. 13, *Brain Sciences*. 2023.
9. Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Vol. 35, *Neuropsychopharmacology*. 2010.
10. Ehlers A, Clark DM. A cognitive model of posttraumatic stress disorder. *Behaviour Research and Therapy*. 2000;38(4).
11. Foa EB, Hembree EA, Rothbaum BO. Prolonged exposure therapy for PTSD: Emotional processing of traumatic experiences: Therapist guide. *Treatments that work*. 2007.
12. de Jongh A, de Roos C, El-Leithy S. State of the science: Eye movement desensitization and reprocessing (EMDR) therapy. *J Trauma Stress*. 2024;37(2).
13. Mann SK, Marwaha R, Torricco TJ. Posttraumatic Stress Disorder. *Clinical Psychology: A Global Perspective* [Internet]. 2024 Feb 25 [cited 2024 Nov 10];191–208. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559129/>
14. Raskind MA, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, et al. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. *New England Journal of Medicine*. 2018;378(6).
15. Bessel A, Van Kolk D. The psychobiology and psychopharmacology of PTSD. *Hum Psychopharmacol*. 2001;16(SUPPL. 1).
16. Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, et al. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. *Focus (Madison)*. 2023;21(3).
17. Lewis BR, Byrne K. A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder. *Focus (Madison)*. 2023;21(3).
18. Andrus M. A Review of “The Body Keeps the Score: Brain, Mind and Body in the Healing of Trauma.” *Art Therapy*. 2015;32(4).
19. Maples-Keller JL, Bunnell BE, Kim SJ, Rothbaum BO. The use of virtual reality technology in the treatment of anxiety and other psychiatric disorders. Vol. 25, *Harvard Review of Psychiatry*. 2017.